A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
about
Comparative analysis of genes frequently regulated by drugs based on connectivity map transcriptome data.A Potential New Mechanism of Arsenic Carcinogenesis: Depletion of Stem-Loop Binding Protein and Increase in Polyadenylated Canonical Histone H3.1 mRNA.Artificial neural network classifier predicts neuroblastoma patients' outcomeContextualizing the Genes Altered in Bladder Neoplasms in Pediatric andTeen Patients Allows Identifying Two Main Classes of Biological ProcessesInvolved and New Potential Therapeutic TargetsChromatin assembly factor 1, subunit A (P150) facilitates cell proliferation in human hepatocellular carcinomaNeuroblastoma treatment in the post-genomic era.Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.Gene expression profiling for targeted cancer treatment.TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells.Application of CRISPR/Cas9 to the study of brain development and neuropsychiatric disease.Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastomap53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.Elevated expression of thyroid hormone receptor-interacting protein 13 drives tumorigenesis and affects clinical outcome.Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells.
P2860
Q33757949-A3C41743-3885-4CAC-9AE7-AC268181B957Q35751961-8B9D2F4D-F812-4AFB-A178-A0663FEE962FQ36276501-385DCD78-09ED-4E55-84C5-3549F8377DB5Q36658489-220766F8-AB36-40CC-8D50-665A049F7638Q37074912-7F8EB2EF-2B6F-4B92-9E4B-CAAF2347CA60Q37633731-CA9E67A7-F51A-45D4-83FA-904ACFEC72D7Q37696208-9295B4F8-BCD3-4DC5-837D-61C1CFBABD8AQ38259249-FF08486E-DF50-453D-90D2-3DD70AACB55BQ38944038-7AC4DB46-5B45-4BCD-91AF-89555443FC76Q39333331-91EE239E-F0A6-4FDF-AA85-A6F77D2A967EQ42282780-15B6A230-49D6-4DBC-85BC-FC7C1573D0DDQ48689521-195CB13C-EA0C-4B94-A4E9-A324BD57694EQ49160323-F0B24FD1-B40C-42B2-9785-C1ABDEC1D3A3Q50551376-0FDEB193-1D43-48C3-8621-15728DE63CCFQ52728024-C4BCC383-10FA-4249-A519-2395F4980D85
P2860
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
@ast
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
@en
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
@nl
type
label
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
@ast
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
@en
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
@nl
prefLabel
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
@ast
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
@en
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
@nl
P2093
P2860
P50
P3181
P1433
P1476
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
@en
P2093
Eveline Barbieri
Gian Paolo Tonini
Jason M Shohet
Paris Stowers
Zaowen Chen
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0079843
P407
P577
2013-11-19T00:00:00Z